Bubs aims for China Food and Drug registration

Company News

by Rachael Jones

Bubs Australia (ASX:BUB) has entered into a binding Manufacturing Agreement with Australia Deloraine Dairy as a critical step towards achieving China Food and Drug Administration (CFDA) registration.

Australia Deloraine Dairy is one of only 15 licenced facilities in Australia authorised by Certification and Accreditation Administration of the People's Republic of China (CNCA) to produce infant formula products eligible for importation into China, under the regulatory requirements administered by CFDA.

Bubs Australia Chairman, Dennis Lin says there is an increasing demand for goat milk based infant formula in China, especially in Mother and Baby stores.

Shares in Bubs Australia (ASX:BUB) closed flat at 80c yesterday. 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.